Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Cash Flow (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Net Cash Flow for 6 consecutive years, with -$7.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 237.91% to -$7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, up 450.13% year-over-year, with the annual reading at $2.7 million for FY2025, 450.13% up from the prior year.
  • Net Cash Flow hit -$7.3 million in Q4 2025 for Insight Molecular Diagnostics, down from -$5.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $51.8 million in Q1 2021 to a low of -$15.2 million in Q1 2022.
  • Historically, Net Cash Flow has averaged $211000.0 across 5 years, with a median of -$5.0 million in 2023.
  • Biggest YoY gain for Net Cash Flow was 1041.85% in 2021; the steepest drop was 5764.38% in 2021.
  • Year by year, Net Cash Flow stood at -$7.7 million in 2021, then plummeted by 36.39% to -$10.5 million in 2022, then surged by 58.76% to -$4.4 million in 2023, then surged by 221.26% to $5.3 million in 2024, then plummeted by 237.91% to -$7.3 million in 2025.
  • Business Quant data shows Net Cash Flow for IMDX at -$7.3 million in Q4 2025, -$5.7 million in Q3 2025, and -$6.7 million in Q2 2025.